news
FDA Clears MiniMed Fit, Medtronic's Seven-Day Tubeless Insulin Pump
Medtronic received FDA clearance for the MiniMed Fit, its first tubeless patch pump delivering insulin for up to seven days. The device doubles the standard three-day wear window of category leader Omnipod. It cuts weekly skin punctures and site rotations in half for people managing insulin-dependent diabetes.
Medtronic received FDA clearance for the MiniMed Fit, its first tubeless patch pump delivering insulin for up to seven days. The device doubles the standard three-day wear window of category leader Omnipod. It cuts weekly skin punctures and site rotations in half for people managing insulin-dependent diabetes.
The architecture take
Seven days of wear instead of three sounds like a convenience tweak until you calculate the physical toll of site changes. Every cannula insertion triggers an acute local inflammatory response, leaves scar tissue, and interrupts the quiet background of your day. Doubling the wear window cuts skin punctures in half. Insulet has owned the tubeless patch pump market with Omnipod for nearly two decades at a strict 72-hour limit, mostly because insulin degrades under body heat and cannulas clog. Medtronic pushing stability to seven days means fewer alarms, less daily cognitive overhead, and steadier basal delivery when your schedule goes sideways. I know people who track their fasting glucose and cortisol spikes purely around site-change mornings because the anticipation alone moves the needle. Friction matters to compliance. When a medical device fades into the background of a shower or a workout, blood sugar numbers usually follow. Next up is full closed-loop sensor pairing, which will decide if this actually steals real market share.